BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS
Topline data expected in 4Q 2020 NEW YORK , July 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc . (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that final participant dosing has been administered in the Phase 3 pivotal
View HTML
Toggle Summary BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar
Lead investigators to discuss BrainStorm's newly announced Phase 2 trial Alzheimer's disease on July 8, 2020 at 8.15 AM NEW YORK , July 1, 2020 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will
View HTML
Toggle Summary BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease
Protocol for the proposed multi-national trial has been submitted for EU regulatory approval   Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer's Disease program on July 8, 2020 at 8:15 AM ET NEW YORK , June 24, 2020 /PRNewswire/ -- BrainStorm Cell
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index
NEW YORK , June 23, 2020 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc . (NasdaqCM: BCLI),  a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the
View HTML
Toggle Summary BrainStorm Granted SME Status by the European Medicines Agency
NEW YORK , June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency’s
View HTML
Toggle Summary BrainStorm to Present at the Raymond James Human Health Innovations Conference
Management to Host One-on-One Investment Meetings NEW YORK , June 11, 2020 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits , CEO and Ralph Kern , MD, MHSc, President
View HTML
Toggle Summary The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
Research Study to Use Data and Samples from NurOwn® Phase 3 Clinical Trial WASHINGTON , June 9, 2020 /PRNewswire/ -- The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology
View HTML
Toggle Summary BrainStorm to Participate in BIO Digital 2020
Management to Host One-on-One Partnering Meetings NEW YORK , June 3, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern , M.D, President and Chief Medical Officer will
View HTML
Toggle Summary BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020
The fully enrolled placebo-controlled Phase 3 trial is evaluating NurOwn® investigational treatment in ALS patients   All patients have received at least 2 doses of NurOwn®   Completion of all dosing is expected by July 2020 NEW YORK , June 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies NEW YORK , May 27, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced
View HTML
Toggle Summary BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
Conference Call and Webcast Today at 8:30 a.m. Eastern Time ALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data Readout NEW YORK , May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of cellular therapies for neurodegenerative
View HTML
Toggle Summary BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
NEW YORK, N.Y. , and TEL AVIV, Israel , May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today a lease agreement with the Tel Aviv Sourasky Medical Center (“Sourasky) in
View HTML
Toggle Summary BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
NEW YORK , May 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that new data highlighting the immunomodulatory effects of NurOwn ® on B and T regulatory function
View HTML
Toggle Summary BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update
Thursday, May 7, 2020, 8:30 a.m. EDT NEW YORK , April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a
View HTML
Toggle Summary BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority
NEW YORK and PETACH TIKVAH, Israel , April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd.
View HTML
Toggle Summary David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer
International Pharmaceutical Veteran to Lead Global Business and Commercial Development Ralph Kern , MD, MHSc, Promoted to President NEW YORK , April 01, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ: BCLI ), a leading developer of cellular therapies for neurodegenerative
View HTML
Toggle Summary BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors
Prof. Frenkel, Chairman of the Group of Thirty (G-30) Board of Trustees, Former Chairman of JPMorgan Chase International and Former Governor of the Bank of Israel Joins the Board to Support the Company’s Global Expansion NEW YORK , March 31, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics
View HTML
Toggle Summary BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones Call Time: Wednesday, March 18 th at 8.30 am EST NEW YORK , March 16, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ:
View HTML
Toggle Summary BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share
NEW YORK , March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC , a healthcare-focused family
View HTML
Toggle Summary Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial
NEW YORK and BOSTON , Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that Partners MS Center at Brigham and Women’s Hospital ,
View HTML
Toggle Summary BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019
Conference Call and Webcast @ 8:00 a.m. Eastern Time Today NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended
View HTML
Toggle Summary BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference
NEW YORK , Feb. 17, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will
View HTML
Toggle Summary BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS
NEW YORK , Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc ., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company recently held a high level meeting with the U.S.
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update
NEW YORK , Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth
View HTML
Toggle Summary BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
NEW YORK , Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO and President, will provide an update of the Company’s
View HTML
Toggle Summary BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®
NEW YORK , Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent
View HTML
Toggle Summary BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit
NEW YORK and LOS ANGELES , Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern , MD, MHSc, Chief Operating Officer and Chief Medical Officer, will
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week
NEW YORK , Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President and Chief Executive Officer, will provide a corporate overview at the
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds